FDA Approves NEVIRAPINE — Mylan Pharmaceuticals Inc.

Mylan Pharmaceuticals Inc. secured the 2014 approval of ANDA 205651 for the oral formulation of Nevirapine, potentially increasing generic accessibility for this antiretroviral medication. The approval of this formulary staple allows the pharmaceutical giant to compete aggressively in the market, impacting shelf availability and pricing dynamics for HIV treatment therapies.